We develop transformative medicines and technologies by building agile, focused companies called Vants.
Roivant was founded in 2014 with the goal of developing and delivering medicines to patients faster and more efficiently
01
Roivant has built 20+ portfolio companies (Vants)
Our Vants have conducted 9 Phase 3 trials (the last 8 of which have been successful), and launched VTAMA®, (tapinarof) cream, 1%, for the topical treatment of plaque psoriasis in adults
02
$3B Upfront Strategic Transaction
In 2019, we consummated a $3B upfront strategic transaction with our partners at Sumitomo Pharma, and we have continued to build a broad and differentiated pipeline of drugs and drug candidates
03
Diverse leadership and employee base
We have worked to ensure an open, diverse, and inclusive culture, while building a leadership team, board of directors and broader employee base that reflects these values.
Our vant creation Process:

Roivant empowers a global team of innovators from within and beyond the biopharmaceutical industry to tackle the most pressing challenges in healthcare today.
Filter by Role

Matt Gline
Chief Executive Officer

Eric Venker, MD
President & Chief Operating Officer

Mayukh Sukhatme, MD
President & Chief Investment Officer

Frank Torti, MD
Vant Chair

Amy Mahery
Chief Commercial Officer

Srini Ramanathan, PhD
Chief Development Officer

Richard Pulik
Chief Financial Officer

Rakhi Kumar
Chief Accounting Officer

Jo Chen
General Counsel

Matt Maisak, PhD
Chief Operating Officer, Roivant Platforms

Alex Gasner
EVP, Roivant Health

Kelly Graff
Head of People

Vivek Ramaswamy
Chairman

Melissa Epperly
Director

Ilan Oren
Director

Daniel Gold
Director

Hiroshi Nomura
Director

James C. Momtazee
Director

Keith Manchester
Director

Iván Cornella-Taracido, PhD
Vice President of Translational Chemical Biology

Huafeng Xu, PhD
Chief Technology Officer

Eric Valeur, PhD
Vice President, Head of Drug Discovery

Jason Imbriglio, PhD
Vice President, Discovery Chemistry

Tudor Oprea, MD, PhD
Vice President, Translational Informatics


Learn more about our work
Sign up for our latest announcements and upcoming presentations

Advancing medicines that matter
View our broad and differentiated pipeline of investigational drugs.